Fibrosis Completed Phase 2 Trials for Pirfenidone (DB04951)

Also known as: Fibrosis (morphologic abnormality) / Fibrosis (qualifier value) / Fibrosis NOS

IndicationStatusPhase
DBCOND0012375 (Fibrosis)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02161952Pirfenidone, an Antifibrotic and Antiinflammatory DrugTreatment
NCT00001959Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)Treatment